Peter Young

Though M&A activity and equity market outputs have been mixed, and pandemic challenges linger on, the outlooks for pharma and biotech remain stable—driven by R&D gains, record IPO levels.

Examining the key biopharma stock numbers and industry trends from a year that challenged the conduct of business and market stability like never before.

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

A review of market performance and trends in 2018 and first quarter of 2019 for the life sciences industry.

What the new rules mean for Chinese-related investments and acquisitions in the US.

The increase in new drug approvals and candidates in development are good signs for pharma and biotech, but both sectors face continued pricing, cost, and healthcare policy-related challenges ahead.

Exploring the prospects-and related challenges-for Chinese life science as it aggressively pursues new growth areas.

2017 was a year of swings and momentum for the pharma and biotech markets. Is more stable footing ahead?

With the soaring valuations of companies in the public and M&A markets now seemingly a distant memory, the challenge for pharma and biotech business will be choosing just the right overall mix of M&A, licensing, and partnering.

For ethical pharma companies, there continues to be a wide variety of tools to acquire revenues and pipeline drugs, but the valuations are challenging, writes Peter Young.